BORDERLINE RESECTABLE PANCREATIC ADENOCARCINOMA
Clinical trials for BORDERLINE RESECTABLE PANCREATIC ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new BORDERLINE RESECTABLE PANCREATIC ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for BORDERLINE RESECTABLE PANCREATIC ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for tough pancreatic cancers: experimental drug PTM-101 tested with chemo
Disease control Recruiting nowThis early-phase trial is testing a new drug called PTM-101 given along with standard chemotherapy before surgery for people with borderline resectable or locally advanced pancreatic cancer. The study aims to find the safest dose and see if the combination can shrink tumors enoug…
Matched conditions: BORDERLINE RESECTABLE PANCREATIC ADENOCARCINOMA
Phase: PHASE1 • Sponsor: PanTher Therapeutics • Aim: Disease control
Last updated May 17, 2026 04:18 UTC
-
New chemo sequence aims to shrink pancreatic tumors before surgery
Disease control Recruiting nowThis study tests whether giving two different chemotherapy combinations one after the other can shrink pancreatic tumors enough to allow successful surgery. About 64 adults with borderline resectable or locally advanced pancreatic cancer will receive gemcitabine plus nab-paclitax…
Matched conditions: BORDERLINE RESECTABLE PANCREATIC ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Wake Forest University Health Sciences • Aim: Disease control
Last updated May 17, 2026 04:15 UTC
-
Triple attack on pancreatic cancer: new hope for patients
Disease control Recruiting nowThis study tests a new approach for people with pancreatic cancer that can be surgically removed. Before surgery, patients receive a combination of chemotherapy, immunotherapy, and targeted radiation. After surgery, they continue with chemotherapy and immunotherapy. The goal is t…
Matched conditions: BORDERLINE RESECTABLE PANCREATIC ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Amsterdam UMC, location VUmc • Aim: Disease control
Last updated May 11, 2026 20:51 UTC
-
New combo targets tough pancreatic cancer in 40-patient trial
Disease control Recruiting nowThis study tests a new drug combination (HRS-4642, nimotuzumab, and chemotherapy) in 40 people with a specific type of pancreatic cancer that has a KRAS G12D mutation and is borderline removable. The goal is to see if this treatment can shrink tumors enough for successful surgery…
Matched conditions: BORDERLINE RESECTABLE PANCREATIC ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Zhejiang University • Aim: Disease control
Last updated May 07, 2026 18:39 UTC
-
New hope for pancreatic cancer: immune boosting drug combo trial launches
Disease control Recruiting nowThis study tests whether adding two new drugs (zimberelimab and quemliclustat) to standard chemotherapy can help shrink pancreatic tumors that are either borderline removable or have spread locally. The goal is to make surgery possible and improve survival. About 56 adults with u…
Matched conditions: BORDERLINE RESECTABLE PANCREATIC ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Apr 29, 2026 15:02 UTC